Skip to main content
Eli LillyPartnership

Eli Lilly Partners With Hims & Hers to Expand GLP-1 Access

Source: Autobound Signal API · 114 signals tracked for Eli Lilly · updated

Get Eli Lilly's live signals in Claude or ChatGPT, or by API

AskWhat changed at Eli Lilly this week? Use Autobound signals for lilly.com.

What happened

Eli Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics, and physical AI.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

An important element of the agreement is the commitment to maintaining independent clinical decision-making. Providers operating through Hims & Hers will continue to determine which treatment is appropriate for each individual, rather than prescribing medicines based on the commercial arrangement. This distinction is significant in a market where demand for obesity medicines has created increased attention around the availability, sourcing and regulation of treatments. Providing access to Lilly's FDA-approved products through the platform establishes a direct relationship between the pharmaceutical manufacturer and the digital healthcare provider. NVIDIA CEO: Jensen Huang | HQ: Santa Clara, California NVIDIA is a US technology company specialising in accelerated computing and artificial intelligence. Eli Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics and physical AI. Insilico Medicine CEO: Alex Zhavoronkov | HQ: Hong Kong Insilico Medicine is an AI-powered drug discovery company. Eli Lilly expanded its partnership with Insilico in 2026 through a deal worth up to US$2.75bn, combining Insilico's AI platforms with Eli Lilly's drug development expertise to advance novel oral medicines. CVS Health CEO: David Joyner | HQ: Woonsocket, Rhode Island Eli Lilly is partnering with CVS to expand access to...

Keep reading with a free account

The rest of this article, and every signal for Eli Lilly, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

More partnership signals at other companies

The full record

From the Signal API record

Extraction

Confidence
90%
Detected
Nov 8, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Eli Lilly and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Eli Lilly this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/146f45c3-b502-89d0-08d5-12232e4ed08f returns this record as JSON. POST /v1/companies/enrich returns every signal for lilly.com.

{
  "signal_id": "146f45c3-b502-89d0-08d5-12232e4ed08f",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-11-08T09:02:50+00:00",
  "company": {
    "name": "Eli Lilly",
    "domain": "lilly.com"
  },
  "data": {
    "url": "https://healthcare-digital.com/news/eli-lilly-partners-with-hims-hers-to-expand-glp-1-access",
    "title": "Eli Lilly Partners With Hims & Hers to Expand GLP-1 Access - Healthcare Digital",
    "excerpt": "An important element of the agreement is the commitment to maintaining independent clinical decision-making. Providers operating through Hims & Hers will continue to determine which treatment is appropriate for each individual, rather than prescribing medicines based on the commercial arrangement. This distinction is significant in a market where demand for obesity medicines has created increased attention around the availability, sourcing and regulation of treatments. Providing access to Lilly's FDA-approved products through the platform establishes a direct relationship between the pharmaceutical manufacturer and the digital healthcare provider. NVIDIA CEO : Jensen Huang | HQ : Santa Clara, California NVIDIA is a US technology company specialising in accelerated computing and artificial intelligence. Eli Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics and physical AI. Insilico Medicine CEO : Alex Zhavoronkov | HQ : Hong Kong Insilico Medicine is an AI-powered drug discovery company. Eli Lilly expanded its partnership with Insilico in 2026 through a deal worth up to US$2.75bn, combining Insilico’s AI platforms with Eli Lilly’s drug development expertise to advance novel oral medicines. CVS Health CEO : David Joyner | HQ : Woonsocket, Rhode Island Eli Lilly is partnering with CVS to expand access to...",
    "summary": "Eli Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics, and physical AI.",
    "planning": true,
    "image_url": "https://assets.bizclikmedia.net/1200/6aa1b2c333e7ff701f3643466afd7991:caa2a2a16de97725feb5ccf6178fac4f/hims-and-hers-eli-lilly.jpg.jpg",
    "confidence": 0.9,
    "published_at": "2026-11-08T09:02:50Z",
    "article_sentence": "Eli Lilly and NVIDIA are investing up to US$1bn over five years in an AI co-innovation lab focused on drug discovery, robotics and physical AI.",
    "related_company_name": "NVIDIA",
    "related_company_domain": "nvidia.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.